Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch

 
• By Mandy Jackson

Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.

FDA Approved typed words on a vintage typewriter
Tukysa was approved for second-line or later HER2-positive breast cancer

More from New Products

More from Scrip